Nasus Pharma Ltd. Ordinary Shares (NSRX)
8.0000
+0.3900 (5.12%)
NYSE · Last Trade: Nov 4th, 5:16 PM EST
Detailed Quote
| Previous Close | 7.610 |
|---|---|
| Open | 8.000 |
| Bid | 3.050 |
| Ask | 8.340 |
| Day's Range | 8.000 - 8.000 |
| 52 Week Range | 5.900 - 9.990 |
| Volume | 4,383 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 4,462 |
Chart
News & Press Releases
Could Nasal Powders Be the Next Revolution in Emergency Medicine?
Every year, thousands of patients die from anaphylactic shock despite carrying life-saving epinephrine. The reason may be simpler than expected: fear of needles. Studies show up to 25% of adults experience needle phobia, yet nearly all emergency medications still require injection. This disconnect between patient psychology and drug delivery technology represents both a healthcare failure and a multi-billion dollar opportunity.
Via AB Newswire · November 3, 2025
The Underdog Disruptor: Why Nasus Pharma Could Be the Sleeper Stock Ready to Shake Up Billion-Dollar Markets
The Bottom Line : Millions of Americans rely on EpiPen every single day. Nasus Pharma (NYSE:NSRX) is developing a simple powder-based nasal spray alternative that could change the game. The company just recently IPO’d and still under the radar, but their proven platform has the potential to open multiple multi-billion-dollar markets - making this a rare early chance to potentially invest before most of Wall Street catches on.
Via AB Newswire · October 13, 2025
Via Benzinga · October 3, 2025
Via Benzinga · September 30, 2025
Nasus Pharma Receives $22 Price Target and Buy Rating From Laidlaw & Company
Nasus Pharma (AMEX: NSRX) has been initiated with coverage by Laidlaw & Company, which assigned a Buy rating and a 12-month price target of $22 in a report dated September 29, 2025. These views and projections are those of Laidlaw and its analyst team, not of Nasus Pharma. The full report is available directly from Laidlaw representatives. As of the market close on September 28. 2025, NSRX was trading at $8 per share.
Via AB Newswire · September 29, 2025